StatPlus, Inc.   Report issue

For profit Phase 1
Founded: Taipei Taiwan (1998)

Organization Overview

First Clinical Trial
2019
NCT04185246
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

StatPlus,Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

perflutren protein-type a microspheres (Optison) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Diseases (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1